SCHEMBL23620703

SCHEMBL23620703

CC#CCNC(=O)COCCOC(COc1cccc(C(N)=O)c1)N=[N+]=[N-]

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FURIN P09958 1/20 0.35
▸ PRMT5 O14744 1/20 0.34
▸ WDR77 Q9BQA1 1/20 0.34
▸ SMN1; SMN2 Q16637 2/20 0.33
▸ PARP1 P09874 1/20 0.33
▸ KMT2A Q03164 3/20 0.33
▸ MEN1 O00255 2/20 0.33
▸ TAAR1 Q96RJ0 1/20 0.33
▸ ALDH1A1 P00352 2/20 0.33
▸ F10 P00742 2/20 0.31
▸ OPRK1 P41145 1/20 0.31
▸ POLB P06746 1/20 0.31
▸ TDP1 Q9NUW8 1/20 0.31
▸ MAPT P10636 2/20 0.31
▸ KDM4E B2RXH2 1/20 0.31
▸ NPC1 O15118 1/20 0.31
▸ RAB9A P51151 1/20 0.31
▸ HSD17B10 Q99714 1/20 0.31
▸ L3MBTL1 Q9Y468 1/20 0.31
▸ SMPD1 P17405 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26010471 0.88 ALDH1A1 (0.37) PRMT5WDR77SMN1; SMN2KMT2AMEN1
SCHEMBL23106220 0.88 ALDH1A1 (0.37) PRMT5WDR77SMN1; SMN2KMT2AMEN1
SCHEMBL24002371 0.87 ALDH1A1 (0.37) SMN1; SMN2KMT2AMEN1TAAR1ALDH1A1
SCHEMBL14611470 0.84 PARP1 (0.37) PARP1KMT2AMEN1TAAR1ALDH1A1
SCHEMBL21575565 0.84 KMT2A (0.43) PARP1KMT2AMEN1TAAR1ALDH1A1
SCHEMBL26167941 0.83 MAOB (0.41) SMN1; SMN2KMT2AMEN1TAAR1ALDH1A1
SCHEMBL26319090 0.80 MAOB (0.40) SMN1; SMN2KMT2AMEN1TAAR1ALDH1A1
SCHEMBL22327196 0.80 ALDH1A1 (0.36) PRMT5WDR77SMN1; SMN2KMT2AMEN1
SCHEMBL26167764 0.80 ALDH1A1 (0.36) SMN1; SMN2KMT2AMEN1TAAR1ALDH1A1
SCHEMBL24370727 0.80 SMN1; SMN2 (0.45) SMN1; SMN2KMT2AMEN1TAAR1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210206794-A1 REVERSIBLY BLOCKED NUCLEOSIDE ANALOGUES AND THEIR USE MGI TECH CO., LTD. (CN) 2021-07-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210206794-A1 REVERSIBLY BLOCKED NUCLEOSIDE ANALOGUES AND THEIR USE NSUN2, NME2, ADAR FURIN 1459/4885PRMT5 1871/4885WDR77 981/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback